AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer
May 15 2017 - 9:30AM
Business Wire
The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today
issued the following statement regarding the passing of its Lead
Director Henri A. Termeer.
“We are deeply saddened at the loss of a visionary, mentor,
colleague and dear friend, Henri A. Termeer. Henri’s wisdom,
foresight and persistence fundamentally changed our industry, which
exists to serve patients suffering from devastating diseases. His
passion for taking on the biggest challenges in medicine has made,
and continues to make, a tremendous difference for so many. He has
been a role model and an inspiration for countless others to do the
same. We are privileged to have worked with Henri to pursue his
vision. Our thoughts are with his family.”
About AVEO
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted therapeutics for oncology
and other areas of unmet medical need. The Company is focused on
seeking to develop and commercialize its lead candidate tivozanib,
a potent, selective, long half-life inhibitor of vascular
endothelial growth factor 1, 2 and 3 receptors, in North America as
a treatment for renal cell carcinoma and other cancers. AVEO is
leveraging multiple partnerships aimed at developing and
commercializing tivozanib in oncology indications outside of North
America, and at progressing its pipeline of novel therapeutic
candidates in cancer and cachexia (wasting syndrome). For more
information, please visit the company’s website at
www.aveooncology.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170515005863/en/
AVEO:Argot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024